These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15786695)

  • 1. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
    Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
    J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
    Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
    Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
    Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
    J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
    Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani GS
    Anticancer Res; 2003; 23(1B):733-6. PubMed ID: 12680176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
    Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia.
    Lissoni P; Mandalà M; Giani L; Malugani F; Secondino S; Zonato S; Rocco F; Gardani G
    Neuro Endocrinol Lett; 2000; 21(5):405-408. PubMed ID: 11452236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
    Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
    Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
    Morfeld KA; Ball RL; Brown JL
    J Zoo Wildl Med; 2014 Sep; 45(3):569-76. PubMed ID: 25314824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
    Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
    J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist therapy in hyperprolactinemia.
    Webster J
    J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
    Ferrari C; Barbieri C; Caldara R; Mucci M; Codecasa F; Paracchi A; Romano C; Boghen M; Dubini A
    J Clin Endocrinol Metab; 1986 Oct; 63(4):941-5. PubMed ID: 3745407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
    Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
    Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
    De Luis DA; Becerra A; Lahera M; Botella JI; Valero ; Varela C
    J Endocrinol Invest; 2000; 23(7):428-34. PubMed ID: 11005266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
    Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
    Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.